Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities researchers at HC Wainwright raised their FY2029 EPS estimates for Aldeyra Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings of $1.10 per share for the year, up from their prior estimate of $1.00. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share.
Other equities research analysts have also issued research reports about the stock. BTIG Research decreased their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Wall Street Zen upgraded shares of Aldeyra Therapeutics to a "sell" rating in a research report on Wednesday.
Check Out Our Latest Stock Analysis on Aldeyra Therapeutics
Aldeyra Therapeutics Price Performance
Shares of NASDAQ:ALDX traded down $0.03 during midday trading on Tuesday, reaching $2.22. The company's stock had a trading volume of 704,068 shares, compared to its average volume of 790,462. The business's fifty day simple moving average is $3.12 and its 200-day simple moving average is $4.63. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The company has a market capitalization of $132.97 million, a P/E ratio of -2.29 and a beta of 0.92.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08.
Insider Buying and Selling
In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. This represents a 36.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 9.60% of the company's stock.
Institutional Trading of Aldeyra Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Kingdon Capital Management L.L.C. bought a new stake in shares of Aldeyra Therapeutics in the 1st quarter valued at about $4,479,000. Raymond James Financial Inc. acquired a new position in Aldeyra Therapeutics during the fourth quarter valued at approximately $3,628,000. Invesco Ltd. increased its stake in Aldeyra Therapeutics by 1,575.7% in the first quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company's stock valued at $2,882,000 after purchasing an additional 471,231 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in Aldeyra Therapeutics by 114.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company's stock valued at $3,233,000 after purchasing an additional 345,748 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Aldeyra Therapeutics by 456.3% in the first quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company's stock worth $2,257,000 after purchasing an additional 321,992 shares during the period. Institutional investors own 59.71% of the company's stock.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Recommended Stories
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
